Skip to main content
SpringerLink
Log in

Tumour Genotype and Response to Cytotoxic Gene Therapy

  • Chapter
Manufacturing of Gene Therapeutics

Abstract

The development of cancer is a multifactorial process and the result of alterations that affect different cellular machineries resulting ultimately in deregulated proliferation. The rapid progress in elucidating the participating signalling pathways involved in tumourigenesis made clear that the direct or indirect disturbance of both cell cycle regulation and the cellular death programmes, i.e. apoptosis, are the major players determining the switch from normal to malignant growth. When the damage is done and a tumour has developed, the further disruption of cell growth and apoptosis control is influenced by a wide variety of factors including the factors regulating genetic and chromosomal stability (e.g. DNA repair pathways and cell cycle checkpoints) and the tumour cell microenvironment, e.g. cell-to-cell and cell-to-matrix interactions and angiogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Denning, C., and J. D. Pitts. 1997. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 8:1825.

    Article  PubMed  CAS  Google Scholar 

  2. Freeman, S. M., C. N. Abboud, K. A. Whartenby, C. H. Packman, D. S. Koeplin, F. L. Moolten, and G. N. Abraham. 1993. The “bystander effect”: tumour regression when a fraction of the tumour mass is genetically modified. Cancer Res 53:5274.

    PubMed  CAS  Google Scholar 

  3. Andrade-Rozental, A. F., R. Rozental, M. G. Hopperstad, J. K. Wu, F. D. Vrionis, and D. C. Spray. 2000. Gap junctions: the “kiss of death” and the “kiss of life”. Brain Res Brain Res Rev 32:308.

    Article  PubMed  CAS  Google Scholar 

  4. Roth, J. A., D. Nguyen, D. D. Lawrence, B. L. Kemp, C. H. Carrasco, D. Z. Ferson, W. K. Hong, R. Komaki, J. J. Lee, J. C. Nesbitt, K. M. Pisters, J. B. Putnam, R. Schea, D. M. Shin, G. L. Walsh, M. M. Dolormente, C. I. Han, F. D. Martin, N. Yen, K. Xu, L. C. Stephens, T. J. McDonnell, T. Mukhopadhyay, and D. Cai. 1996. Retrovirus-mediated wild-type p53 gene transfer to tumours of patients with lung cancer. Nat Med 2:985.

    Article  PubMed  CAS  Google Scholar 

  5. Clayman, G. L., A. K. el-Naggar, S. M. Lippman, Y. C. Henderson, M. Frederick, J. A. Merritt, L. A. Zumstein, T. M. Timmons, T. J. Liu, L. Ginsberg, J. A. Roth, W. K. Hong, P. Bruso, and H. Goepfert. 1998. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:2221.

    PubMed  CAS  Google Scholar 

  6. Clayman, G. L., D. K. Frank, P. A. Bruso, and H. Goepfert. 1999. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 5:1715.

    PubMed  CAS  Google Scholar 

  7. Zwacka, R. M., and M. G. Dunlop. 1998. Gene therapy for colon cancer. Hematol Oncol Clin North Am 12:595.

    Article  PubMed  CAS  Google Scholar 

  8. Wildner, O. 1999. In situ use of suicide genes for therapy of brain tumours. Ann Med 31:421.

    Article  PubMed  CAS  Google Scholar 

  9. Wildner, O., J. C. Morris, N. N. Vahanian, H. Ford, Jr., W. J. Ramsey, and R. M. Blaese. 1999. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 6:57.

    Article  PubMed  CAS  Google Scholar 

  10. Allay, J. A., M. S. Steiner, Y. Zhang, C. P. Reed, J. Cockroft, and Y. Lu. 2000. Adenovirus pl6 gene therapy for prostate cancer. World J Urol 18:111.

    Article  PubMed  CAS  Google Scholar 

  11. Fueyo, J., C. Gomez-Manzano, V. K. Puduvalli, P. Martin-Duque, R. Perez-Soler, V. A. Levin, W. K. Yung, and A. P. Kyritsis. 1998. Adenovirus-mediated p16 transfer to glioma cells induces Gl arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12:665.

    PubMed  CAS  Google Scholar 

  12. Fueyo, J., C. Gomez-Manzano, W. K. Yung, T. J. Liu, R. Alemany, T. J. McDonnell, X. Shi, J. S. Rao, V. A. Levin, and A. P. Kyritsis. 1998. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumour growth in vitro and in vivo. Nat Med 4:685.

    Article  PubMed  CAS  Google Scholar 

  13. Guo-Chang, F., and W. Chu-Tse. 2000. Transfer of pl4ARF gene in drug-resistant human breast cancer MCF-7/Adr cells inhibits proliferation and reduces doxorubicin resistance. Cancer Lett 158:203.

    Article  PubMed  CAS  Google Scholar 

  14. Alemany, R., C. Balague, and D. T. Curiel. 2000. Replicative adenoviruses for cancer therapy. Nat Biotechnol 18:723.

    Article  PubMed  CAS  Google Scholar 

  15. Alemany, R., C. Gomez-Manzano, C. Balague, W. K. Yung, D. T. Curiel, A. P. Kyritsis, and J. Fueyo. 1999. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252:7.

    Article  Google Scholar 

  16. Fueyo, J., C. Gomez-Manzano, R. Alemany, P. S. Lee, T. J. McDonnell, P. Mitlianga, Y. X. Shi, V. A. Levin, W. K. Yung, and A. P. Kyritsis. 2000. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19:2.

    Article  PubMed  CAS  Google Scholar 

  17. Heise, C., and D. H. Kirn. 2000. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 105:847.

    Article  PubMed  CAS  Google Scholar 

  18. Wildner, O., R. M. Blaese, and J. C. Morris. 1999. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 59:410.

    PubMed  CAS  Google Scholar 

  19. Yohn, D. S., W. M. Hammon, R. W. Atchison, and B. C. Casto. 1968. Oncolytic potentials of nonhuman viruses for human cancer. II. Effects of five viruses on heterotransplantable human tumours. J Natl Cancer Inst 41:525.

    Google Scholar 

  20. Daniel, P. T. 2000. Dissecting the pathways to death. Leukemia 14:2035.

    Article  PubMed  CAS  Google Scholar 

  21. Krammer, P. H., J. Dhein, H. Walczak, I. Behrmann, S. Mariani, B. Matiba, M. Fath, P. T. Daniel, E. Knipping, M. O. Westendorp, K. Stricker, C. Bäumler, S. Hellbardt, M. Germer, M. E. Peter, and K.-M. Debatin. 1994. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 142:175.

    Article  PubMed  CAS  Google Scholar 

  22. Bargou, R. C., P. T. Daniel, M. Y. Mapara, K. Bommert, C. Wagener, B. Kallinich, H. D. Royer, and B. Dörken. 1995. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumour cells correlates with resistance towards apoptosis. Int J Cancer 60:854.

    Article  PubMed  CAS  Google Scholar 

  23. Bargou, R. C., C. Wagener, K. Bommert, W. Arnold, P. T. Daniel, M. Y. Mapara, E. Grinstein, H. D. Royer, and B. Dörken. 1996. Blocking the transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis and induces tumour growth in SCID mice. J Exp Med 183:1205.

    Article  PubMed  CAS  Google Scholar 

  24. Bargou, R. C., C. Wagener, K. Bommert, M. Y. Mapara, P. T. Daniel, W. Arnold, M. Dietel, H. Guski, A. Feller, H. D. Royer, and B. Dörken. 1996. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces rumour growth in SCID mice. J Clin Invest 91:2651.

    Article  Google Scholar 

  25. Prokop, A., T. Wieder, I. Sturm, F. Essmann, K. Seeger, C. Wuchter, W.-D. Ludwig, G. Henze, B. Dörken, and P. T. Daniel. 2000. Relapse in childhood acute lymphoblastic leukemia is associated with decrease of Bax/Bcl-2- ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14:1606.

    Article  PubMed  CAS  Google Scholar 

  26. Sturm, I., C. H. Kohne, G. Wolff, H. Petrowsky, T. Hillebrand, S. Hauptmann, M. Lorenz, B. Dörken, and P. T. Daniel. 1999. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17:1364.

    PubMed  CAS  Google Scholar 

  27. Wagener, C., R. C. Bargou, P. T. Daniel, K. Bommert, M. Y. Mapara, H. D. Royer, and B. Dörken. 1996. Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 67:138.

    Article  PubMed  CAS  Google Scholar 

  28. Eischen, C. M., J. D. Weber, M. F. Roussel, C. J. Sherr, and J. L. Cleveland. 1999. Disruption of the ARF-Mdm2-p53 tumour suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13:2658.

    Article  PubMed  CAS  Google Scholar 

  29. Maelandsmo, G. M., V. A. Florenes, E. Hovig, T. Oyjord, O. Engebraaten, R. Holm, A. L. Borresen, and O. Fodstad. 1996. Involvement of the pRb/pl6/cdk4/cyclin Dl pathway in the tumourigenesis of sporadic malignant melanomas. Br J Cancer 13:909.

    Article  Google Scholar 

  30. Palmero, I., and G. Peters. 1996. Perturbation of cell cycle regulators in human cancer. Cancer Surv 27:351.

    PubMed  CAS  Google Scholar 

  31. Schutte, M., R. H. Hruban, J. Geradts, R. Maynard, W. Hilgers, S. K. Rabindran, C. A. Moskaluk, S. A. Hahn, I. Schwarte-Waldhoff, W. Schmiegel, S. B. Baylin, S. E. Kern, and J. G. Herman. 1997. Abrogation of the Rb/pl6 tumour-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57:3126.

    PubMed  CAS  Google Scholar 

  32. Shapiro, G. I., C. D. Edwards, L. Kobzik, J. Godleski, W. Richards, D. J. Sugarbaker, and B. J. Rollins. 1995. Reciprocal Rb inactivation and pl6INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505.

    PubMed  CAS  Google Scholar 

  33. Shapiro, G. I., J. E. Park, C. D. Edwards, L. Mao, A. Merlo, D. Sidransky, M. E. Ewen, and B. J. Rollins. 1995. Multiple mechanisms of pl6INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 55:6200.

    PubMed  CAS  Google Scholar 

  34. Sherr, C., and J. Weber. 2000. The ARF/p53 pathway. Curr Opin Gen Develop 10:94.

    Article  CAS  Google Scholar 

  35. Tsihlias, J., L. Kapusta, and J. Slingerland. 1999. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 50:401.

    Article  PubMed  CAS  Google Scholar 

  36. Vidal, A., and A. Koff. 2000. Cell-cycle inhibitors: three families united by a common cause. Gene 247:1.

    Article  PubMed  CAS  Google Scholar 

  37. Petrowsky, H., I. Sturm, O. Graubitz, D. A. Kooby, E. Staib-Sebler, C. Gog, C.-H. Köhne, T. Hillebrand, P. T. Daniel, Y. Fong, and M. Lorenz. 2001. Relevance of proliferation and K-ras mutation in colorectal liver metastasis. Eur J Surg Oncol 21:80.

    Article  Google Scholar 

  38. Soussi, T., K. Debouche, and C. Béroud. 2000. P53 website and analysis of p53 gene mutations in cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 15:105.

    Article  PubMed  CAS  Google Scholar 

  39. Sturm, I., S. Papadopoulos, T. Hillebrand, T. Benter, H.-J. Lück, G. Wolff, B. Dörken, and P. T. Daniel. 2000. Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene. Int J Cancer 87:517.

    Article  PubMed  CAS  Google Scholar 

  40. Pardee, A. B. 1989. Gl events and regulation of cell proliferation. Science 246:603.

    Article  PubMed  CAS  Google Scholar 

  41. Grana, X., J. Garriga, and X. Mayol. 1998. Role of the retinoblastoma protein family, pRB, pl07 and pl30 in the negative control of cell growth. Oncogene 11:3365.

    Google Scholar 

  42. King, K. L., and J. A. Cidlwoski. 1998. Cell cycle regulation and apoptosis. Annu Rev Physiol 60:601.

    Article  PubMed  CAS  Google Scholar 

  43. Chow, K. N., and D. C. Dean. 1996. Domains A and B in the Rb pocket interact to form a transcriptional repressor motif. Mol Cell Biol 16:4862.

    PubMed  CAS  Google Scholar 

  44. Müller, H., and K. Helin. 2000. The E2F transcription factors: key regulators of cell proliferation. Biochim Biophys Acta 1470:M1.

    PubMed  Google Scholar 

  45. Yamasaki, L. 1999. Balancing proliferation and apoptosis in vivo: the Goldilocks theory of E2F/DP action. Biochim Biophys Acta 1423:M9.

    PubMed  CAS  Google Scholar 

  46. Knudsen, E. S., C. Buckmaster, T. T. Chen, J. R. Feramisco, and J. Y. Wang. 1998. Inhibition of DNA synthesis by RB: effects on Gl/S transition and S-phase progression. Genes Dev 12:2278.

    Article  PubMed  CAS  Google Scholar 

  47. Kato, J. Y. 1997. Control of Gl progression by D-type cyclins: key event for cell proliferation. Leukemia 11:347.

    PubMed  Google Scholar 

  48. Ohtani, K., J. DeGregori, and J. R. Nevins. 1995. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A 92:12146.

    Article  PubMed  CAS  Google Scholar 

  49. Sherr, C. J., and J. M. Roberts. 1999. CDK inhibitors: positive and negative regulators of Gl-phase progression. Genes Dev 13:1501.

    Article  PubMed  CAS  Google Scholar 

  50. Waldman, T., C. Lengauer, K. W. Kinzler, and B. Vogelstein. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:773.

    Article  Google Scholar 

  51. Hollander, M., M. Sheikh, D. Bulavin, K. Lundgren, L. Augeri-Henmueller, R. Shehee, T. Molinaro, K. Kim, E. Tolosa, J. Ashwell, M. Rosenberg, Q. Zhan, P. Fernandez-Salguero, W. Morgan, C. Deng, and A. Fornace. 1999. Genomic instability in Gadd45a-deficient mice. Nat Genet 23:176.

    Article  PubMed  CAS  Google Scholar 

  52. Chinnaiyan, A. M., K. O’Rourke, M. Tewari, and V. M. Dixit. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81:505.

    Article  PubMed  CAS  Google Scholar 

  53. Blagosklonny, M. V. 2000. Cell death beyond apoptosis. Leukemia 14:1502.

    Article  PubMed  CAS  Google Scholar 

  54. Wieder, T., F. Essmann, A. Prokop, K. Schmelz, K. Schulze-Osthoff, R. Beyaert, B. Dörken, and P. T. Daniel. 2001. Activation of Caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor ligand interaction and occurs downstream of Caspase-3. Blood 91.1378.

    Article  Google Scholar 

  55. Kroemer, G., and J. C. Reed. 2000. Mitochondrial control of death. Nat Med 6:513.

    Article  PubMed  CAS  Google Scholar 

  56. Shimizu, S., and Y. Tsujimoto. 2000. Proapoptotic BH3-only Bcl-2 family members induce cytochrome c release, but not mitochondrial membrane potential loss, and do not directly modulate voltage-dependent anion channel activity. Proc Natl Acad Sci USA 91:577.

    Article  Google Scholar 

  57. Van der Heiden, M. G., and C. B. Thompson. 1999. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol 1:E209.

    Article  Google Scholar 

  58. Desagher, S., A. Osen-Sand, A. Nichols, R. Eskes, S. Montessuit, S. Lauper, K. Maundrell, B. Antonsson, and J. Martinou. 1999. Bid-induced Conformational Change of Bax Is Responsible for Mitochondrial Cytochrome c Release during Apoptosis. J Cell Biol 144:891.

    Article  PubMed  CAS  Google Scholar 

  59. Lorenzo, H. K., S. A. Susin, J. Penninger, and G. Kroemer. 1999. Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ 6:516.

    Article  PubMed  CAS  Google Scholar 

  60. Li, H., H. Zhu, C. Xu, and J. Yuan. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491.

    Article  PubMed  CAS  Google Scholar 

  61. Luo, X., I. Budihardjo, H. Zou, C. Slaughter, and X. Wang. 1998. Bid, a Bcl-2 interacting protein, mediates cytochrome c release in response to activation of cell surface death receptors. Cell 94:481.

    Article  PubMed  CAS  Google Scholar 

  62. Perez, D., and E. White. 2000. TNF-alpha signals apoptosis through a bid-dependent conformational change in Bax that is inhibited by E1B 19K. Mol Cell 6:53.

    PubMed  CAS  Google Scholar 

  63. Walker, A., S. T. Taylor, J. A. Hickman, and C. Dive. 1997. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells. Cancer Res 51:1939.

    Google Scholar 

  64. Graeber, T., C. Osmanian, T. Jacks, D. Housman, C. Koch, S. Lowe, and A. Giaccia.1996.Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 319 88.

    Article  Google Scholar 

  65. Daniel, P. T., A. Pezzutto, and B. Dörken. 1999. Humoral immunotherapy and the use of monoclonal antibodies. In: Textbook of Malignant Haematology, ed. by Degos, l., Linch, D. C., and Lowenberg, B., Martin Dunitz Ltd., London:425.

    Google Scholar 

  66. Cascallo, M., E. Mercade, G. Capella, F. Lluis, C. Fillat, A. M. Gomez-Foix, and A. Mazo. 1999. Genetic background determines the response to adenovirus-mediated wild- type p53 expression in pancreatic tumour cells. Cancer Gene Ther 6:428.

    Article  PubMed  CAS  Google Scholar 

  67. McCurrach, M. E., T. M. Connor, C. M. Knudson, S. J. Korsmeyer, and S. W. Lowe. 1997.bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci U S A 94:2345.

    Article  PubMed  CAS  Google Scholar 

  68. Daniel, P. T., K. T. Pun, S. Ritschel, I. Sturm, J. Holler, B. Dörken, and R. Brown. 1999. Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumour growth in severe combined immunodeflcient mice. Blood 94:1100.

    PubMed  CAS  Google Scholar 

  69. Krajewski, S., C. Blomqvist, K. Franssila, M. Krajewska, V. M. Wasenius, E. Niskanen, S. Nordling, and J. C. Reed. 1995. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471.

    PubMed  CAS  Google Scholar 

  70. Gascoyne, R. D., M. Krajewska, S. Krajewsky, J. M. Connors, and J. C. Reed. 1997. Prognostic significance of BAX protein expression in diffuse aggressive Non-Hodgkin’s lymphoma. Blood 90:3173.

    PubMed  CAS  Google Scholar 

  71. Tai, Y. T., S. Lee, E. Niloff, C. Weisman, T. Strobel, and S. A. Cannistra. 1998. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 16:2583.

    PubMed  CAS  Google Scholar 

  72. Friess, H., Z. Lu, H. U. Graber, A. Zimmermann, G. Adler, M. Korc, R. M. Schmid, and M. W. Büchler. 1998. bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43:414.

    Article  PubMed  CAS  Google Scholar 

  73. Miyashita, T., and J. C. Reed. 1995. Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293.

    Article  PubMed  CAS  Google Scholar 

  74. Rampino, N., H. Yamamoto, Y. Ionov, Y. Li, H. Sawai, J. C. Reed, and M. Perucho. 1997. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 215:967.

    Article  Google Scholar 

  75. Reed, J. A., F. Loganzo, Jr., C. R. Shea, G. J. Walker, J. F. Flores, J. M. Glendening, J. K. Bogdany, M. J. Shiel, F. G. Haluska, J. W. Fountain, and et al. 1995. Loss of expression of the pl6/cyclin-dependent kinase inhibitor 2 tumour suppressor gene in melanocytic lesions correlates with invasive stage of tumour progression. Cancer Res 55:2713.

    PubMed  CAS  Google Scholar 

  76. Hu, Y. X., H. Watanabe, K. Ohtsubo, Y. Yamaguchi, A. Ha, T. Okai, and N. Sawabu. 1997. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 3:1473.

    PubMed  CAS  Google Scholar 

  77. Fizzotti, M., G. Cimino, S. Pisegna, G. Alimena, C. Quartarone, F. Mandelli, P. G. Pelicci, and F. Lo Coco. 1995. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 85:2685.

    PubMed  CAS  Google Scholar 

  78. Heyman, M., O. Rasool, L. Borgonovo Brandter, Y. Liu, D. Grander, S. Soderhall, G. Gustavsson, and S. Einhorn. 1996. Prognostic importance of pl5INK4B and pl6INK4 gene inactivation in childhood acute lymphocytic leukemia. J Clin Oncol 14:1512.

    PubMed  CAS  Google Scholar 

  79. Kratzke, R. A., T. M. Greatens, J. B. Rubins, M. A. Maddaus, D. E. Niewoehner, G. A. Niehans, and J. Geradts. 1996. Rb and pl6INK4a expression in resected non-small cell lung rumours. Cancer Res 56:3415.

    PubMed  CAS  Google Scholar 

  80. Huang, C. I., T. Taki, M. Higashiyama, N. Kohno, and M. Miyake. 2000. p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung. Br J Cancer 82:374.

    Article  PubMed  CAS  Google Scholar 

  81. Goldstein, A. M., M. C. Fraser, J. P. Struewing, C. J. Hussussian, K. Ranade, D. P. Zametkin, L. S. Fontaine, S. M. Organic, N. C. Dracopoli, W. H. Clark, Jr. et al. 1995. Increased risk of pancreatic cancer in melanoma-prone kindreds with pl6INK4 mutations. N Engl J Med 333:970.

    Article  PubMed  CAS  Google Scholar 

  82. Hussussian, C. J., J. P. Struewing, A. M. Goldstein, P. A. Higgins, D. S. Ally, M. D. Sheahan, W. H. Clark, Jr., M. A. Tucker, and N. C. Dracopoli. 1994. Germline pl6 mutations in familial melanoma. Nat Genet 8:15.

    Article  PubMed  CAS  Google Scholar 

  83. Ruas, M., S. Brookes, N. Q. McDonald, and G. Peters. 1999. Functional evaluation of tumour-specific variants of pl6INK4a/CDICN2A: correlation with protein structure information. Oncogene 18:5423.

    Article  PubMed  CAS  Google Scholar 

  84. Ruas, M., and G. Peters. 1998. The pl6INK4a/CDKN2A tumour suppressor and its relatives. Biochim Biophys Acta 131S.F115.

    Google Scholar 

  85. Craig, C., M. Kim, E. Ohri, R. Wersto, D. Katayose, Z. Li, Y. H. Choi, B. Mudahar, S. Srivastava, P. Seth, and K. Cowan. 1998. Effects of adenovirus-mediated pl6INK4A expression on cell cycle arrest are determined by endogenous pl6 and Rb status in human cancer cells. Oncogene 16:265.

    Article  PubMed  CAS  Google Scholar 

  86. Halvorsen, O. J., J. Hostmark, S. Haukaas, P. A. Hoisaeter, and L. A. Akslen. 2000. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 88:416.

    Article  PubMed  CAS  Google Scholar 

  87. Kanoe, H., T. Nakayama, H. Murakami, T. Hosaka, H. Yamamoto, Y. Nakashima, T. Tsuboyama, T. Nakamura, M. S. Sasaki, and J. Toguchida. 1998. Amplification of the CDK4 gene in sarcomas: tumour specificity and relationship with the RB gene mutation. Anticancer Res 18:2317.

    PubMed  CAS  Google Scholar 

  88. Wei, G., F. Lonardo, T. Ueda, T. Kim, A. G. Huvos, J. H. Healey, and M. Ladanyi. 1999. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12ql3 amplicons. Int J Cancer 80:199.

    Article  PubMed  CAS  Google Scholar 

  89. Wölfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wölfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K. H. Meyer zum Büschenfelde, and D. Beach. 1995. A pl6INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281.

    Article  PubMed  Google Scholar 

  90. Kataoka, M., S. Wiehle, F. Spitz, G. Schumacher, J. A. Roth, and R. J. Cristiano. 2000. Down-regulation of bcl-2 is associated with pl6INK4-mediated apoptosis in non-small cell lung cancer cells. Oncogene 19:1589.

    Article  PubMed  CAS  Google Scholar 

  91. Kamijo, T., S. Bodner, E. van de Kamp, D. H. Randle, and C. J. Sherr. 1999. Tumour spectrum in ARF-deficient mice. Cancer Res 59:2217.

    PubMed  CAS  Google Scholar 

  92. Kamijo, T., F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. J. Sherr. 1997. Tumour suppression at the mouse INK4a locus mediated by the alternative reading frame product pl9ARF. Cell 91:649.

    Article  PubMed  CAS  Google Scholar 

  93. Gomez-Manzano, C., J. Fueyo, F. Alameda, A. P. Kyritsis, and W. K. Yung. 1999. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Int J Mol Med 3:81.

    PubMed  CAS  Google Scholar 

  94. Nevins, J. R. 1992. E2F: a link between the Rb tumour suppressor protein and viral oncoproteins. Science 258:424.

    Article  PubMed  CAS  Google Scholar 

  95. Leone, G., J. Degregori, L. Jakoi, J. G. Cook, and J. R. Nevins. 1999. Collaborative role of E2F transcriptional activity and Gl cyclin-dependent kinase activity in the induction of S phase. Proc. Natl. Acad. Sci. USA 96:6626-6631.

    Article  PubMed  CAS  Google Scholar 

  96. Barker, D. D., and A. J. Berk. 1987. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156:107.

    Article  PubMed  CAS  Google Scholar 

  97. Goodrum, F. D., and D. A. Ornelles. 1998. p53 status does not determine outcome of E1B 55-kDa mutant adenovirus lytic infection. J Virol 12:9479.

    Google Scholar 

  98. Harada, J. N., and A. J. Berk. 1999. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 13:5333-5344.

    Google Scholar 

  99. Rothmann, T., A. Hengstermann, N. J. Whitaker, M. Scheffher, and H. zur Hausen. 1998. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumour cells. J Virol 12:9470-9478.

    Google Scholar 

  100. Turnell, A. S., R. J. Grand, and P. H. Gallimore. 1999. The replicative capacities of large E1B group A and group C adenoviruses are independent of host cell p53 status. J Virol 13:2074.

    Google Scholar 

  101. Ries, S. J., C. H. Brandts, A. S. Chung, C. H. Biederer, B. C. Hann, E. M. Lippner, F. McCormick, and W. M. Korn. 2000. Loss of pl4ARF in tumour cells facilitates replication of the adenovirus mutant dll 520 (ONYX-015). Nat Med 6:1128.

    Article  PubMed  CAS  Google Scholar 

  102. Heise, C., T. Hermiston, L. Johnson, G. Brooks, A. Sampson-Johannes, A. Williams, L. Hawkins, and D. Kim. 2000. An adenovirus E1 A mutant that demonstrates potent and selective systemic anti-tumoural efficacy. Nat Med 6:1134.

    Article  PubMed  CAS  Google Scholar 

  103. Schuler, M., C. Rochlitz, J. A. Horowitz, J. Schlegel, A. P. Perruchoud, F. Kommoss, C. T. Bolliger, H. U. Kauczor, P. Dalquen, M. A. Fritz, S. Swanson, R. Herrmann, and C. Huber. 1998. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 9:2075.

    Article  PubMed  CAS  Google Scholar 

  104. Swisher, S. G., and J. A. Roth. 1998. Gene therapy for human lung cancers. Surg Oncol Clin N Am 1:603.

    Google Scholar 

  105. Swisher, S. G., J. A. Roth, J. Nemunaitis, D. D. Lawrence, B. L. Kemp, C. H. Carrasco, D. G. Connors, A. K. El-Naggar, F. Fossella, B. S. Glisson, W. K. Hong, F. R. Khuri, J. M. Kurie, J. J. Lee, J. S. Lee, M. Mack, J. A. Merritt, D. M. Nguyen, J. C. Nesbitt, R. Perez-Soler, K. M. Pisters, J. B. Putnam, Jr., W. R. Richli, M. Savin, M. K. Waugh, and et al. 1999. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91:763.

    Article  PubMed  CAS  Google Scholar 

  106. Pagliaro, L. C. 2000. Gene therapy for bladder cancer. World J Urol 18.148.

    Article  PubMed  CAS  Google Scholar 

  107. Habib, N. A., H. J. Hodgson, N. Lemoine, and M. Pignatelli. 1999. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum Gene Ther 10:2019.

    Article  PubMed  CAS  Google Scholar 

  108. Herman, J. R., H. L. Adler, E. Aguilar-Cordova, A. Rojas-Martinez, S. Woo, T. L. Timme, T. M. Wheeler, T. C. Thompson, and P. T. Scardino. 1999. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 10:1239.

    Article  PubMed  CAS  Google Scholar 

  109. Trask, T. W., R. P. Trask, E. Aguilar-Cordova, H. D. Shine, P. R. Wyde, J. C. Goodman, W. J. Hamilton, A. Rojas-Martinez, S. H. Chen, S. L. Woo, and R. G. Grossman. 2000. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumours. Mol Ther 1:195.

    Article  PubMed  CAS  Google Scholar 

  110. Klatzmann, D., C. A. Valery, G. Bensimon, B. Marro, O. Boyer, K. Mokhtari, B. Diquet, J. L. Salzmann, and J. Philippon. 1998. A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 9:2595.

    Article  PubMed  CAS  Google Scholar 

  111. Shand, N., F. Weber, L. Mariani, M. Bernstein, A. Gianella-Borradori, Z. Long, A. G. Sorensen, and N. Barbier. 1999. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumour transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 10:2325.

    Article  PubMed  CAS  Google Scholar 

  112. Klatzmann, D., P. Cherin, G. Bensimon, O. Boyer, A. Coutellier, F. Charlotte, C. Boccaccio, J. L. Salzmann, and S. Hereon. 1998. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther 9:2585.

    Article  PubMed  CAS  Google Scholar 

  113. Sterman, D. H., J. Treat, L. A. Litzky, K. M. Amin, L. Coonrod, K. Molnar-Kimber, A. Recio, L. Knox, J. M. Wilson, S. M. Albelda, and L. R. Kaiser. 1998. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9:1083.

    Article  PubMed  CAS  Google Scholar 

  114. Hasenburg, A., X. W. Tong, A. Rojas-Martinez, C. Nyberg-Hoffman, C. C. Kieback, A. L. Kaplan, R. H. Kaufman, I. Ramzy, E. Aguilar-Cordova, and D. G. Kieback. 1999. Thymidine kinase (TK) gene therapy of solid tumours: valacyclovir facilitates outpatient treatment. Anticancer Res 19:2163.

    PubMed  CAS  Google Scholar 

  115. Crystal, R. G., E. Hirschowitz, M. Lieberman, J. Daly, E. Kazam, C. Henschke, D. Yankelevitz, N. Kemeny, R. Silverstein, A. Ohwada, T. Russi, A. Mastrangeli, A. Sanders, J. Cooke, and B. G. Harvey. 1997. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 8:985.

    Article  PubMed  CAS  Google Scholar 

  116. Pandha, H. S., L. A. Martin, A. Rigg, H. C. Hurst, G. W. Stamp, K. Sikora, and N. R. Lemoine. 1999. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 17:2180.

    PubMed  CAS  Google Scholar 

  117. Anonymous. 1999. Onyx plans phase III trial of ONYX-015 for head & neck cancer. Oncologist 4:432.

    Google Scholar 

  118. Gilly, F. N., A. Beaujard, J. Bienvenu, V. Trillet Lenoir, O. Glehen, D. Thouvenot, C. Malcus, M. Favrot, C. Dumontet, C. Lombard-Bohas, F. Garbit, P. Y. Gueugniaud, J. Vignal, M. Aymard, F. Touraine Moulin, M. Roos, A. Pavirani, and M. Courtney. 1999. Gene therapy with Adv-IL-2 in unresectable digestive cancer: phase I-II study, intermediate report. Hepatogastroenterology 46 Suppl 1:1268.

    PubMed  CAS  Google Scholar 

  119. Okada, H., I. F. Pollack, M. T. Lotze, L. D. Lunsford, D. Kondziolka, F. Lieberman, D. Schiff, J. Attanucci, H. Edington, W. Chambers, P. Robbins, J. Baar, D. Kinzler, T. Whiteside, and E. Elder. 2000. Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene- modified autologous tumour to elicit an immune response. Hum Gene Ther 11:637.

    Article  PubMed  Google Scholar 

  120. Stewart, A. K., N. J. Lassam, I. C. Quirt, D. J. Bailey, L. E. Rotstein, M. Krajden, S. Dessureault, S. Gallinger, D. Cappe, Y. Wan, C. L. Addison, R. C. Moen, J. Gauldie, and F. L. Graham. 1999. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 6:350.

    Article  PubMed  CAS  Google Scholar 

  121. Wollenberg, B., Kastenbauer, H. Mundl, J. Schaumberg, A. Mayer, M. Andratschke, S. Lang, C. Pauli, R. Zeidler, S. Ihrler, Lohrs, K. Naujoks, and R. Rollston. 1999. Gene 112. therapy-phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoural injection of hIL-2 plasmids formulated in DOTMA/Chol. Hum Gene Ther 10:141.

    Article  PubMed  CAS  Google Scholar 

  122. Rini, B. I., L. M. Selk, and N. J. Vogelzang. 1999. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 5:2766.

    PubMed  CAS  Google Scholar 

  123. Daniel, P. T., A. Kroidl, S. Cayeux, R. Bargou, T. Blankenstein, and B. Dörken. 1997. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol 159:3808.

    PubMed  CAS  Google Scholar 

  124. Daniel, P. T., A. Kroidl, J. Kopp, I. Sturm, G. Moldenhauer, B. Dörken, and A. Pezzutto. 1998. Immunotherapy of B-cell lymphoma with CD3xl9 bispecific antibodies: costimulation via CD28 prevents “veto” apoptosis of antibody-targeted cytotoxic T cells. Blood 92:4750.

    PubMed  CAS  Google Scholar 

  125. Daniel, P. T., C. Scholz, F. Essmann, J. Westermann, A. Pezzutto, and B. Dörken. 1999. CD95/Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism. Exp Hematol 21:1402.

    Article  Google Scholar 

  126. Krammer, P. H. 1999. CD95(APO-l/Fas)-mediated apoptosis: live and let die. Adv Immunol 71:163.

    Article  PubMed  CAS  Google Scholar 

  127. Sturm, I., H. Petrowsky, R. Volz, M. Lorenz, S. Radetzki, T. Hillebrand, G. Wolff, S. Hauptmann, B. Dörken, P.T. Daniel. 2001. Analysis of p53/BAX/pl6ink4a/CDKN2 in esophageal squamous cell carcinoma: High BAX and p16ink4a/CDKN2 identifies patients with good prognosis. J Clin Oncol: in press.

    Google Scholar 

  128. Friedrich K, T. Wieder, C. von Haefen, S. Radetzki, K. Schulze-Osthoff, R. Jänicke, B. Dörken, P.T. Daniel. 2001. Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cells with acquired drug resistance. Oncogene: in press.

    Google Scholar 

  129. Nemunaitis, J., F. Khuri, I. Ganly, J. Arseneau, M. Posner, E. Vokes, J. Kuhn, T. McCarty, S. Landers, A. Blackburn, L. Romel, B. Randlev, S. Kaye, and D. Kirn. 2001. Phase II trial of intratumoural administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol:19:289.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Oncology, and Tumour Immunology, University Medical Centre Charité, Lindenberger Weg 80, 13125, Berlin, Germany

    Peter T. Daniel, Bernhard Gillissen & Isrid Sturm

  2. Campus Berlin-Buch, Humboldt University Berlin, Lindenberger Weg 80, 13125, Berlin, Germany

    Peter T. Daniel, Bernhard Gillissen & Isrid Sturm

Authors
  1. Peter T. Daniel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernhard Gillissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isrid Sturm
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Littlebourne, Kent, England

    G. Subramanian

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Daniel, P.T., Gillissen, B., Sturm, I. (2002). Tumour Genotype and Response to Cytotoxic Gene Therapy. In: Subramanian, G. (eds) Manufacturing of Gene Therapeutics. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1353-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1353-7_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5512-0

  • Online ISBN: 978-1-4615-1353-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation